PFE vs BMY
Pfizer · Bristol-Myers Squibb
| PFE Pfizer Healthcare | BMY Bristol-Myers Squibb Healthcare | |
|---|---|---|
| Market | ||
| Price | $30.52 +1.90% | $62.48 +1.78% |
| Market cap | $174.0B | $127.6B |
| P/E (TTM) | 40.1 | 13.8 |
| Dividend yield | 5.38% | 4.58% |
| 52-week range | $23.62 – $30.67 | $43.20 – $68.64 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 | Bristol-Myers Squibb: The Forensic Case That The Patent Cliff Math Has Already Been Solved May 27, 2026 |
| Latest earnings | ||
| Reported | — | Oct 29, 2026 |
| Revenue | — | $13.1 billion +7% YoY |
| EPS | — | $1.05 |
| Guidance | — | Guidance raised |
| Revenue growth, last 4 reports | — | +7% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Shared topics: Dividends Patent Cliff
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.